NIH runs the same SBIR set-aside through its own SEED process

The record

The National Institutes of Health administers its SBIR and STTR programs through an office it calls SEED, Small Business Education and Entrepreneurial Development, which states on its own site that “24 of the NIH's Institutes fund small business R&D projects” and that the two programs together make available “$1.4 Billion in Small Business Funding.” SEED's own comparison page states NIH applies the same statutory set-aside figures used government-wide, 3.2 percent of extramural R&D budget for SBIR and 0.45 percent for STTR, alongside the same 40/30 percent STTR work-share floor SBA's Policy Directive states. NIH's own application path runs through company registration, a choice of Phase I, Fast-Track, or Direct-to-Phase-II entry, and direct contact with NIH program staff before submission, a structure SEED presents as specific to its own review process.

What the documents establish

SEED's percentages match the statutory minimums SBA's own Policy Directive states apply to every participating agency, which is a useful check rather than an assumption: NIH's figures are not a separately negotiated rate, but the same government-wide floor other agencies must also meet, confirmed independently by two agencies' own documents rather than one page describing the other. Where the two sources diverge is scope: SBA's Directive states the rule for every agency, while SEED's page adds NIH-specific mechanics, its 24 funding Institutes, its Fast-Track and Direct-to-Phase-II entry paths, and its own eligibility and foreign-disclosure guidance pages, that a general SBA description would not cover.

The operating read

A founder assuming every agency's SBIR set-aside behaves identically is only half right: the percentage floor is common, but the operating path to an award, which Institute reviews a proposal, what registrations precede an application, and whether a Fast-Track or Direct-to-Phase-II route is open, is agency-specific and, at NIH, Institute-specific. This is editorial: a biomedical applicant should treat “talk to NIH staff before applying,” which SEED's own how-to-apply sequence lists as a step, as a materially different norm from agencies that discourage pre-submission contact, and should not assume a Fast-Track combined-phase submission guarantees Phase II funding, since NIH's own guidance ties Phase II to continued review of Phase I progress.

What to check before you decide

Before assuming NIH's small-business process mirrors another agency's, check the following:

• Which of NIH's 24 participating Institutes would review a given proposal, and does that Institute publish its own funding priorities or contacts?
• Does the current set-aside percentage SEED states match the fiscal year and program cited for a specific solicitation?
• Is a Fast-Track or Direct-to-Phase-II path actually open for the technology's stage of development, per SEED's current guidance?

This describes NIH's and SBA's own published guidance as retrieved on 16 September 2026, not application advice; NIH program staff and the specific funding opportunity notice govern any actual submission.